...
首页> 外文期刊>Annals of surgical oncology >Distal gastric cancer and extensive surgery: a new evaluation method based on the study of the status of residual lymph nodes after limited surgery.
【24h】

Distal gastric cancer and extensive surgery: a new evaluation method based on the study of the status of residual lymph nodes after limited surgery.

机译:远端胃癌和广泛手术:一种基于有限手术后残留淋巴结状况研究的新评估方法。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: Curative resection (R0) is the treatment of choice for distal gastric cancer, but it is unclear whether this operation should include a total gastrectomy (TG) with splenectomy and extended (D2) lymph node dissection. A new concept was developed based on the fact that residual metastatic lymph nodes after a limited (D1) subtotal gastrectomy (SG) may be the source of fatal relapse. We conducted a prospective study on patients who had undergone a D2 TG to evaluate whether certain stations left behind after a D1 SG contain metastasis. METHODS: We studied 1207 nodes obtained from 35 eligible patients who underwent a TG within 2 years. Of these patients, 29 fulfilled the criterion for a D2 dissection with curative potential. Numbers of retrieved and tumor-containing nodes by each station according to the Japanese Research Society for Gastric Cancer were documented prospectively in a standardized protocol. All lymph nodes were studied in sections smaller than 2 mm, but emphasis was given to the study of nodes from stations 1 and 2 (paracardial right and left), station 10 (splenic hilum), and stations 7 through 12 (around celiac axis, and in hepatoduodenal ligament) that can be dissected with a TG, splenectomy, and D2 dissection, respectively. For quality control of D2 dissection, the numbers of nodes retrieved by each compartment II nodal station (7-12) documented by a pathologist were used and compared with proposed reference values. Long-term survival and cumulative risk of relapse were calculated in terms of lymph node status and presence of metastasis in compartment II nodes. RESULTS: A mean total node yield of 37.4 from stations 1-12 and 11.4 from compartment II (stations 7-12) was obtained from 29 patients who had a D2 TG with curative intent. A substantial variation in node yields was found, and sometimes several stations contained no lymph nodes, which suggested an important cause of noncompliance (no yield of lymph nodes detected by the pathologist from that indicated for dissection stations) and difficulties for quality control. No positive node was detected in stations 1, 2, and 10 among patients who had a curative TG with splenectomy. However, substantially high was the incidence of metastasis in compartment II nodes, which was detected in one third of patients with node-positive disease. After 10 years of follow-up, overall survival and relapse rates among R0 D2 patients with negative compartment II nodes (pN0/pN1 disease) were 47% and 44%, respectively. CONCLUSIONS: Our results suggest the necessity of D2 dissection, but not of TG with splenectomy, to achieve an R0 resection for patients with distal gastric carcinoma. A large prospective study based on our protocol and findings may clarify whether a D2 R0 resection would result in a survival benefit.
机译:背景:根治性切除术(R0)是远端胃癌的治疗选择,但尚不清楚该手术是否应包括全胃切除术(TG)脾切除术和扩大(D2)淋巴结清扫术。基于以下事实,提出了一个新的概念:有限的(D1)次全胃切除术(SG)后残留的转移性淋巴结可能是致命性复发的根源。我们对接受D2 TG的患者进行了一项前瞻性研究,以评估D1 SG后留下的某些部位是否包含转移。方法:我们研究了从35名在2年内接受TG的合格患者中获得的1207个淋巴结。在这些患者中,有29位符合具有治愈潜力的D2解剖标准。根据日本胃癌研究协会的资料,每个站点检索到的包含肿瘤的淋巴结的数量均以标准化方案进行了前瞻性记录。所有淋巴结均以小于2 mm的截面进行了研究,但重点是从第1站和第2站(左右心包旁),第10站(脾门)和第7到12站(腹腔轴,和肝十二指肠韧带),可以分别用TG,脾切除术和D2解剖进行解剖。为了对D2解剖进行质量控制,使用了由病理学家记录的每个隔室II节点站(7-12)检索到的结节数,并将其与建议的参考值进行比较。根据淋巴结状态和II区隔中是否存在转移来计算长期生存率和复发的累积风险。结果:29例具有治愈意图的D2 TG患者获得了平均分总产量,分别来自第1-12站的17.4位和第II室(7-12站)的11.4。发现淋巴结的产量有很大的变化,有时几个工作站没有淋巴结,这提示不合规的重要原因(病理学家从解剖工作站显示的淋巴结无产量)和质量控制困难。在脾切除术治愈的TG患者中,在1、2和10站没有检测到阳性淋巴结。但是,在II区淋巴结转移的发生率相当高,这在三分之一淋巴结阳性患者中被检测到。经过10年的随访,II型腔室淋巴结阴性(pN0 / pN1疾病)的R0 D2患者的总生存率和复发率分别为47%和44%。结论:我们的结果表明,对于远端胃癌患者,必须行D2解剖而不是行脾切除术TG,才能实现R0切除。根据我们的方案和发现进行的大规模前瞻性研究可能会阐明D2 R0切除术是否会带来生存益处。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号